POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-167282 | Health Care
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Polyarticular Juvenile Idiopathic Arthritis Drug Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET
7.1 GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Biocon Ltd (India)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Coherus BioSciences Inc (United States)
16.3 Livzon Pharmaceutical Group Inc (China)
16.4 Momenta Pharmaceuticals Inc (United States)
16.5 Mycenax Biotech Inc (Taiwan)
16.6 Oncobiologics Inc (United States)
16.7 Panacea Biotec Ltd (India)
16.8 Regeneron Pharmaceuticals Inc (United States)
16.9 Sandoz International GmbH (Germany)
16.10 UCB SA (Belgium)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeNonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Disease-Modifying Antirheumatic Drugs (DMARDs)
Biologic Agents
Corticosteroids
By Application
Reduces Systemic Inflammation
Prevent Joint Damage
Others
By Distribution Channel
Online
Medical Stores
Clinics
Pharmaceuticals
Others
By Form
Tablet
Capsule
Others
By End-User
Hospital Pharmacy
Retail Pharmacies
Electronic Pharmacy
Companies
Biocon Ltd (India)
Coherus BioSciences Inc (United States)
Livzon Pharmaceutical Group Inc (China)
Momenta Pharmaceuticals Inc (United States)
Mycenax Biotech Inc (Taiwan)
Oncobiologics Inc (United States)
Panacea Biotec Ltd (India)
Regeneron Pharmaceuticals Inc (United States)
Sandoz International GmbH (Germany)
UCB SA (Belgium)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.